- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RARE
Recent news which mentions RARE
From Benzinga
From Benzinga
From Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
From Benzinga
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
May 10, 2022
Tickers
RARE
From Benzinga
From Benzinga
From MarketWatch
From PRLog
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
Earnings Scheduled For February 10, 2022
February 10, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 19, 2022
From Benzinga
These 60 stocks, including DraftKings, Zillow and Virgin Galactic, are down at least 50% from their 2021 highs
November 29, 2021
From MarketWatch
Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript
November 03, 2021
Tickers
RARE
From Motley Fool
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
From Benzinga
Earnings Scheduled For November 2, 2021
November 02, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
September 30, 2021
Tickers
RARE
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
From Benzinga
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
September 27, 2021
Tickers
RARE
From Benzinga
Why Shares of Solid Biosciences Are Jumping Today
September 21, 2021
From Motley Fool
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.